APM2 Antibody

Introduction to APM2 Antibody

APM2 (Adipose Most Abundant Gene Transcript 2 Protein), also designated C10orf116 or ADIRF, is an ~8 kDa protein initially identified in adipose tissue . Recent research has revealed its critical role in modulating chemotherapy resistance, particularly to cisplatin (CDDP), in cancers such as hepatocellular carcinoma (HCC) and gastric cancer (GC) . APM2 antibodies are polyclonal tools developed to detect and study this protein’s expression and functional mechanisms in clinical and experimental settings.

Biological Role and Mechanisms

APM2 is implicated in chemoresistance through its regulatory effects on DNA repair pathways. Key findings include:

• Cisplatin Resistance: APM2 overexpression in HCC cells reduces CDDP sensitivity by upregulating ERCC6L, a DNA repair protein .

• Biomarker Potential: Serum APM2 levels correlate with CDDP response. A cut-off value of 18.7 µg/mL distinguishes sensitive from resistant patients, with 77.3% predictive accuracy in HCC and 100% in GC .

• Tissue Specificity: APM2 is absent in cisplatin-sensitive cell lines but abundant in resistant tumors and adipose tissue .

Antibody Characteristics and Applications

APM2 antibodies are primarily used in research to investigate its role in cancer biology. Key specifications include:

Predictive Value in Cancer Therapy

A 2021 clinical study (n=68 patients) demonstrated:

• Serum APM2 Level: Patients with APM2 >18.7 µg/mL showed significantly reduced CDDP efficacy .

• Mechanistic Insight: APM2 upregulates ERCC6L, enhancing DNA repair and enabling tumor cells to evade CDDP-induced damage .

Clinical Validation

Data derived from serum APM2 analysis in CDDP-treated patients .

Clinical and Research Implications

• Biomarker Utility: APM2 serum levels could guide personalized chemotherapy regimens, avoiding ineffective CDDP use in resistant tumors .

• Therapeutic Targeting: Inhibiting APM2 or its downstream effectors (e.g., ERCC6L) may reverse chemoresistance .

• Commercial Availability: Anti-APM2 antibodies are available from suppliers like Exalpha Biologicals and Thermo Fisher Scientific, facilitating further mechanistic studies .

Limitations and Future Directions

• Current evidence is limited to HCC and GC; broader validation across cancer types is needed.

• The exact molecular pathways linking APM2 to DNA repair remain partially characterized.

• Standardized assays for serum APM2 quantification are not yet widely adopted in clinical practice.